Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06512974 · ClinicalTrials.gov registry record · NA
NeuroTrainer Cognitive Training For Academic Focus
A NA study of ADHD - Combined Type and ADHD Predominantly Inattentive Type, sponsored by NeuroTrainer.
- Recruiting
- Registry status
- NA
- Development phase
- 155
- Enrollment target
- 3
- Study locations
NCT06512974 is a NA study of ADHD - Combined Type and ADHD Predominantly Inattentive Type that is actively recruiting participants, run by NeuroTrainer. The registered enrollment target is 155 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT06512974, a NA study of ADHD - Combined Type and ADHD Predominantly Inattentive Type, is actively recruiting participants, sponsored by NeuroTrainer.
- RECRUITING
- Registry status
- NA
- Development phase
- 155 participants
- Enrollment target
- 3
- Study locations
Study Summary
This clinical trial aims to evaluate the feasibility and efficacy of NeuroTrainer cognitive training in improving attentional and executive control functions in students with and without attention-related difficulties.
Conditions Studied
Interventions
- BEHAVIORAL NeuroTrainer
Study Locations (3)
Michigan
- Marquette Senior High School - Marquette
Nebraska
- Westside High School - Omaha
Wisconsin
- One City Schools - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2024-09-01 |
| Est. Completion | 2026-02-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06512974
The ClinicalTrials.gov registry entry for NCT06512974 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NeuroTrainer, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with ADHD - Combined Type appearing as the primary indexed condition, and to 1 intervention - of which NeuroTrainer is the first listed.
NCT06512974 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Michigan, Nebraska, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06512974 about?
NCT06512974 is a clinical study titled "NeuroTrainer Cognitive Training For Academic Focus". This clinical trial aims to evaluate the feasibility and efficacy of NeuroTrainer cognitive training in improving attentional and executive control functions in students with and without attention-related difficulties.
What is the current status of trial NCT06512974?
This trial is currently recruiting. It is a NA study. The enrollment target is 155 participants. The study started on 2024-09-01. Estimated completion is 2026-02-28.
What conditions does trial NCT06512974 study?
This clinical trial studies the following conditions: ADHD - Combined Type, ADHD Predominantly Inattentive Type, ADHD, Predominantly Hyperactive - Impulsive.
What interventions are being tested in trial NCT06512974?
The interventions under investigation include: NeuroTrainer (BEHAVIORAL).
Who is sponsoring clinical trial NCT06512974?
This trial is sponsored by NeuroTrainer, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06512974 being conducted?
This trial has 3 study locations across Michigan, Nebraska, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ADHD - Combined Type
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.